<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Manifestations of and risk factors for aminoglycoside nephrotoxicity</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Manifestations of and risk factors for aminoglycoside nephrotoxicity</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Manifestations of and risk factors for aminoglycoside nephrotoxicity</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bruce A Molitoris, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul M Palevsky, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 28, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Acute kidney injury is a relatively common complication of therapy with the aminoglycoside antibiotics, with a rise in the plasma creatinine concentration of more than 0.5 to 1 mg/dL (44 to 88 micromol/L) or 50 percent increase in plasma creatinine concentration from baseline occurring in 10 to 20 percent of hospitalized patients [<a href="#rid1">1-4</a>]. In children, aminoglycoside-induced acute kidney injury can be seen in as many as 20 to 33 percent of treated children [<a href="#rid5">5</a>].</p><p>Aminoglycosides are freely filtered across the glomerulus and then partially taken up by, and concentrated in, cortical proximal tubule cells, which is where most of the kidney damage occurs. After administration, up to 5 to 10 percent of the parenteral dose is retained in the kidney cortex, where it can achieve concentrations greatly exceeding the concurrent serum concentration [<a href="#rid6">6</a>]. This preferential sequestration of aminoglycosides in proximal tubule cells accounts for the observation that kidney failure may become clinically apparent as late as several days after the drug has been discontinued. (See  <a class="medical medical_review" href="/d/html/7242.html" rel="external">"Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity"</a>.)</p><p>The manifestations of and risk factors for aminoglycoside nephrotoxicity are reviewed here. Acute tubular necrosis due to ischemia or other insults and the pathogenesis and potential therapy of aminoglycoside nephrotoxicity are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7216.html" rel="external">"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7228.html" rel="external">"Pathogenesis and etiology of ischemic acute tubular necrosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7242.html" rel="external">"Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">MANIFESTATIONS</span></p><p class="headingAnchor" id="H3"><span class="h2">Nonoliguric acute kidney injury</span><span class="headingEndMark"> — </span>Acute kidney injury from aminoglycoside exposure typically manifests with a rise in serum creatinine after five to seven days of therapy. The nonoliguric aspect of the kidney failure is secondary to a loss in renal concentrating ability believed to be the result of distal tubular damage.</p><p>The acute tubular necrosis that occurs from aminoglycoside exposure is unlikely to be severe if detected early, with incremental increases in the plasma creatinine that are usually mild (0.5 to 2 mg/dL [44 to 177 micromol/liter]) [<a href="#rid7">7</a>]. There is also evidence that patients without chronic kidney disease (CKD) are unlikely to develop CKD following a single episode of aminoglycoside-induced acute kidney injury [<a href="#rid8">8</a>]. However, aminoglycoside toxicity can result in progression of preexisting CKD, even precipitating kidney replacement therapy. The urine sediment most commonly shows mild proteinuria, hyaline, and granular casts. The fractional excretion of sodium is generally above 1 percent (<a class="calc calc_professional" href="/d/html/13497.html" rel="external">calculator 1</a>) or, for standard units, (<a class="calc calc_professional" href="/d/html/13499.html" rel="external">calculator 2</a>). (See  <a class="medical medical_review" href="/d/html/7219.html" rel="external">"Fractional excretion of sodium, urea, and other molecules in acute kidney injury"</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Distal tubular dysfunction</span><span class="headingEndMark"> — </span>Distal nephron segments also can be affected in aminoglycoside nephrotoxicity. The two major manifestations of distal dysfunction are polyuria due to decreased concentrating ability and hypomagnesemia due to enhanced urinary losses (see next section) [<a href="#rid1">1,9</a>]. The polyuria is postulated to be secondary to the attenuation in the sensitivity of the collecting-duct epithelium to endogenous antidiuretic hormone in aminoglycoside nephrotoxicity [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Electrolyte abnormalities</span><span class="headingEndMark"> — </span>Hypomagnesemia, hypokalemia, hypocalcemia, and hypophosphatemia are infrequently observed. This is likely secondary to the decrement in proximal tubule transport that occurs during aminoglycoside-induced nephrotoxicity. A Fanconi-like syndrome can occur with glycosuria, aminoaciduria, phosphaturia, and uricosuria. The loss of phosphorus in the urine results in hypophosphatemia [<a href="#rid1">1</a>]. With aminoglycoside nephrotoxicity, magnesium depletion resulting in hypomagnesemia can lead to secondary hypokalemia and hypocalcemia.</p><p>Treatment of aminoglycoside-induced magnesium-wasting consists of the administration of oral or intravenous magnesium supplements. However, the efficacy of this oral regimen is limited by the urinary excretion of most of the extra magnesium. (See  <a class="medical medical_review" href="/d/html/848.html" rel="external">"Hypomagnesemia: Clinical manifestations of magnesium depletion"</a> and  <a class="medical medical_review" href="/d/html/834.html" rel="external">"Hypomagnesemia: Evaluation and treatment"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Course</span><span class="headingEndMark"> — </span>Given that proximal tubules can regenerate, the usual course of aminoglycoside nephrotoxicity is one of recovery of kidney function. The plasma creatinine concentration usually returns to the prior baseline level within 21 days after cessation of therapy. However, resolution of the acute episode may be delayed if the patient remains hypovolemic, septic, or catabolic; in these settings, tubular regeneration cannot occur.</p><p>Irreversible kidney damage is uncommon with acute aminoglycoside nephrotoxicity. However, it may occur with prolonged therapy, even in low doses [<a href="#rid10">10</a>].</p><p>Studies in other forms of reversible acute kidney injury suggest that normalization of the plasma creatinine concentration and even the glomerular filtration rate may not reflect complete recovery. Irreversible nephron loss in this setting may be masked by compensatory hyperfiltration in the remaining normal glomeruli. (See  <a class="medical medical_review" href="/d/html/7225.html" rel="external">"Kidney and patient outcomes after acute kidney injury in adults"</a>.)</p><p>Although a pattern of a nonoliguric acute kidney injury five to seven days after aminoglycoside exposure is suggestive, differentiating aminoglycoside-induced acute kidney injury from other etiologies of acute tubular necrosis can be difficult given that it often occurs in the setting of significant comorbid conditions, sepsis, and concomitant nephrotoxin exposure. In addition, acute kidney injury is frequently multifactorial, and aminoglycoside nephrotoxicity is only one of its components. An essential initial diagnostic step in the diagnosis of aminoglycoside nephrotoxicity is a careful history with attention to potentially reversible etiologies, such as reduced effective arterial volume or urinary tract obstruction. In addition, a review of all imaging procedures for intravenous contrast exposure and medications for concomitant nephrotoxin use is imperative.</p><p class="headingAnchor" id="H7"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>Several risk factors have been identified that increase the risk of aminoglycoside nephrotoxicity [<a href="#rid1">1-3</a>]. The major risk factors are:</p><p class="bulletIndent1"><span class="glyph">●</span>Prolonged duration of therapy</p><p class="bulletIndent1"><span class="glyph">●</span>Advanced age</p><p class="bulletIndent1"><span class="glyph">●</span>Comorbid disease</p><p class="bulletIndent1"><span class="glyph">●</span>Reduced effective arterial volume</p><p class="bulletIndent1"><span class="glyph">●</span>Sepsis</p><p class="bulletIndent1"><span class="glyph">●</span>Concomitant medications</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated plasma aminoglycoside concentrations</p><p class="bulletIndent1"><span class="glyph">●</span>Type of aminoglycoside</p><p class="bulletIndent1"><span class="glyph">●</span>Frequency of dosing</p><p class="bulletIndent1"><span class="glyph">●</span>Serum albumin &lt;3 g/dL</p><p class="bulletIndent1"><span class="glyph">●</span>Anemia</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Prolonged duration of therapy</span><span class="headingEndMark"> — </span>The development of acute kidney injury, as determined by serum creatinine, generally requires at least five to seven days of exposure to aminoglycosides in patients with normal hemodynamic status. Prolonged therapy increases the risk that toxic aminoglycoside concentrations will develop and persist in the kidney cortex.</p><p>For any given aminoglycoside, a direct relationship exists between serum concentrations of aminoglycosides, renal cortical proximal tubule cell concentrations, and nephrotoxicity [<a href="#rid1">1,11,12</a>]. Owing to the renal cortical sequestration of aminoglycosides, the risk of aminoglycoside-induced nephrotoxicity is also increased in patients given the drug in repeated courses separated by a few days or weeks [<a href="#rid1">1</a>]. In contrast, renal cortical accumulation is less when aminoglycosides are given as one large, daily dose, as in once-daily dosing programs, because of the saturable nature of the renal cortical uptake [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/d/html/475.html" rel="external">"Dosing and administration of parenteral aminoglycosides", section on 'Nephrotoxicity'</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Advanced age</span><span class="headingEndMark"> — </span>Advanced age has long been held to be an important risk factor in the development of aminoglycoside nephrotoxicity [<a href="#rid14">14-18</a>]. This increased risk is postulated to be secondary to the impaired capacity for cellular repair and regeneration found in this patient population. In addition, advanced age may result in excessive dosing of aminoglycosides from an overestimation of actual glomerular filtration rate (GFR) by estimated GFR equations. </p><p class="headingAnchor" id="H10"><span class="h2">Comorbid disease</span><span class="headingEndMark"> — </span>A number of comorbid conditions are associated with aminoglycoside-induced kidney disease. Diabetes mellitus and leukemia, for example, increase the risk for aminoglycoside nephrotoxicity [<a href="#rid18">18</a>].</p><p>Early studies of aminoglycoside nephrotoxicity reported increased risk of aminoglycoside nephrotoxicity in patients with chronic kidney disease (CKD). In these studies, however, aminoglycoside concentrations were not pharmacokinetically adjusted, and patients were likely exposed to high serum levels of aminoglycosides with associated nephrotoxicity. Interestingly, subsequent studies showed that patients with higher creatinine clearances were associated with an increased risk of nephrotoxicity [<a href="#rid2">2,14</a>].</p><p>Overall, patients with CKD are at increased risk for aminoglycoside nephrotoxicity because the risk of inadvertent overdosing is greater than in patients with normal kidney function. This increased risk is due to the imprecision of our bedside tools in estimating kidney function and aminoglycoside dosing. Furthermore, patients with CKD have less kidney functional reserve and an attenuated ability to recover from aminoglycoside nephrotoxicity. </p><p>Among patients with advanced liver disease, activation of the renin-angiotensin-aldosterone system may play a pathogenetic role in increasing the risk of aminoglycoside nephrotoxicity [<a href="#rid2">2</a>]. In addition, obstructive jaundice with a plasma bilirubin concentration above 5 mg/dL (85 micromol/L) is associated with an increased risk of aminoglycoside nephrotoxicity [<a href="#rid2">2,19,20</a>]. How obstructive jaundice increases the sensitivity to aminoglycoside toxicity is not known, but either bilirubin or endotoxin (which is absorbed because of decreased bile salt entry into the intestinal lumen) may be involved [<a href="#rid20">20</a>]. The hypoalbuminemia frequently observed in advanced liver disease is also an independent risk factor for aminoglycoside nephrotoxicity [<a href="#rid8">8</a>]. </p><p class="headingAnchor" id="H11"><span class="h2">Reduced effective arterial volume</span><span class="headingEndMark"> — </span>Reduced effective arterial volume results in decreased kidney perfusion, kidney ischemia, and greatly enhances the risk of aminoglycoside nephrotoxicity [<a href="#rid21">21,22</a>]. This can occur in the clinical setting of intravascular volume depletion, heart failure, sepsis, and advanced liver disease. Moreover, kidney ischemia appears to accelerate the time course and severity for aminoglycoside nephrotoxicity.</p><p>Two factors have been postulated to mediate this synergism between the aminoglycoside and kidney ischemia:</p><p class="bulletIndent1"><span class="glyph">●</span>The aminoglycoside interferes with cell energetics, thereby increasing the susceptibility to kidney injury during an ischemic episode [<a href="#rid23">23</a>]. This synergism is most prominent in the S3 segment of the proximal tubule; this segment is particularly sensitive to ischemic injury secondary to minimal reperfusion resulting in continuing hypoxia to the area.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ischemia alters membrane lipids. In particular, there is enhanced phosphatidylinositol (PI) content in the luminal membrane [<a href="#rid24">24</a>]. This results in increased aminoglycoside binding, uptake, and accumulation in the proximal tubular cells of S1, S2, and S3 segments since filtered cationic <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> binds to PI and other acidic phospholipids and is then internalized by endocytosis. This charge interaction has important implications for the development and possible prevention of aminoglycoside nephrotoxicity and is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/7242.html" rel="external">"Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity"</a>.)</p><p></p><p class="headingAnchor" id="H12"><span class="h2">Sepsis</span><span class="headingEndMark"> — </span>In addition to volume depletion, as described above, endotoxin also enhances the nephrotoxicity of the aminoglycosides [<a href="#rid25">25</a>]. Although decreased kidney perfusion due to renal vasoconstriction may play a contributory role, endotoxin also appears to be associated with enhanced drug accumulation in the tubules. How this occurs is not known. (See  <a class="medical medical_review" href="/d/html/7228.html" rel="external">"Pathogenesis and etiology of ischemic acute tubular necrosis"</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Concomitant medications</span><span class="headingEndMark"> — </span>Administration of potentially nephrotoxic medications with aminoglycosides places a patient at increased risk for nephrotoxicity. Implicated medications include <a class="drug drug_general" data-topicid="8482" href="/d/drug information/8482.html" rel="external">furosemide</a>, nonsteroidal antiinflammatory drugs (NSAIDs), angiotensin-converting enzyme inhibitors, <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a>, and <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> [<a href="#rid1">1,2,17,18</a>].</p><p>Initial studies suggested that cephalothin increased the nephrotoxicity of the aminoglycosides [<a href="#rid26">26</a>]. However, patients with sepsis or hypotension were excluded. In this limited population, cephalothin did have a potentiating effect, but the kidney injury was mild, with the plasma creatinine concentration remaining below 2 mg/dL (176 micromol/L) in almost all patients [<a href="#rid26">26</a>].</p><p>In comparison, there seemed to be no increase in toxic effects when all treated patients are included, which more closely simulates the real world [<a href="#rid2">2</a>]. Furthermore, it is unclear if the initial results with cephalothin can be extrapolated to any of the other cephalosporin-type drugs. Evidence suggests that this probably does not occur and that the cephalosporins can be safely given in conjunction with an aminoglycoside [<a href="#rid3">3</a>].</p><p>Although it seems likely that cephalosporins do not have a major effect on aminoglycoside nephrotoxicity, there is suggestive evidence that concurrent administration of a penicillin may actually be protective [<a href="#rid27">27,28</a>]. How this occurs is not known, but decreased tubular uptake of the aminoglycoside may be involved. It must be emphasized, however, that penicillins, particularly carbenicillin, <a class="drug drug_general" data-topicid="9775" href="/d/drug information/9775.html" rel="external">piperacillin</a>, and ticarcillin, can physically complex with the aminoglycosides; as a result, these agents cannot be mixed in the same intravenous infusion.</p><p class="headingAnchor" id="H14"><span class="h2">Elevated plasma drug concentrations</span><span class="headingEndMark"> — </span>Careful monitoring of plasma levels is an important component of aminoglycoside therapy. Impaired kidney function can occur even with perfect control of the plasma level since renal cortical aminoglycoside accumulation increases with time [<a href="#rid29">29,30</a>]. However, the risk is greater in patients receiving divided-dose aminoglycoside therapy who develop high peak plasma drug levels (&gt;10 mcg/mL for <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> and <a class="drug drug_general" data-topicid="10000" href="/d/drug information/10000.html" rel="external">tobramycin</a>) [<a href="#rid1">1,30</a>]. In addition, elevated trough levels (&gt;2.5 mcg/mL) have been associated with nephrotoxicity in a once-daily aminoglycoside dosing program of an older cohort of patients [<a href="#rid15">15</a>].</p><p>Remarkably, whether an elevated trough or peak level contributes to the increased risk of nephrotoxicity with aminoglycosides is not fully elucidated. In one analysis, no causal relationship could be found between a serum peak or trough aminoglycoside level in several reviewed studies [<a href="#rid31">31</a>].</p><p>The therapeutic success observed with once-daily aminoglycoside programs with their associated supratherapeutic levels certainly casts doubt on whether a peak aminoglycoside level increases nephrotoxic risk in this clinical setting. However, an elevated trough level has been shown to increase the nephrotoxic risk in once-daily aminoglycoside programs in older adults [<a href="#rid15">15</a>]. Similarly, in another older patient cohort, an elevated peak level increased aminoglycoside nephrotoxicity with conventional dosing [<a href="#rid15">15</a>].</p><p>Although there remains uncertainty about whether peak or trough levels are primarily responsible for nephrotoxicity, serum monitoring of aminoglycosides is beneficial and recommended due to the following reasons:</p><p class="bulletIndent1"><span class="glyph">●</span>The limitations of our bedside estimates of glomerular filtration rates on which we base our aminoglycoside dosing are often imprecise.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monitoring programs ensure that less toxic antibiotics will be selected in patients with contraindications to aminoglycosides.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>These programs also ensure that appropriate therapeutic doses of antibiotics are given earlier in a patient's therapy.</p><p></p><p>Several researchers have demonstrated the benefits of pharmacokinetically monitoring aminoglycoside therapy. This is especially important since few patients have a known glomerular filtration rate allowing for appropriate modeling of the pharmacokinetics. Among the benefits cited were fewer instances of nephrotoxicity and treatment failure and shorter hospital stays [<a href="#rid32">32-35</a>].</p><p>Serum peak and trough levels should be measured periodically when conventional aminoglycoside dosing is used. Moreover, peak and trough monitoring in conventional dosing is imperative in older patients with obesity. By contrast, once-daily aminoglycoside programs only require a periodic trough level. This trough level is used to determine the timing of the next dose of aminoglycoside. (See  <a class="medical medical_review" href="/d/html/475.html" rel="external">"Dosing and administration of parenteral aminoglycosides"</a>.)</p><p class="headingAnchor" id="H15"><span class="h2">Type of aminoglycoside</span><span class="headingEndMark"> — </span>Not all of the aminoglycosides appear to have the same potential for nephrotoxicity. However, comparing the relative risk of each of the aminoglycosides for nephrotoxicity is problematic due to the variability in the clinical studies regarding the incidence of nephrotoxicity, the use of controls, and the criteria used to define nephrotoxicity.</p><p>Overall, when prospective comparative trials are compared, <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> has the greatest nephrotoxic potential, followed in decreasing order of nephrotoxicity by <a class="drug drug_general" data-topicid="10000" href="/d/drug information/10000.html" rel="external">tobramycin</a>, <a class="drug drug_general" data-topicid="8536" href="/d/drug information/8536.html" rel="external">amikacin</a>, and netilmicin [<a href="#rid1">1,29,36</a>]. Although amikacin and netilmicin are considered less nephrotoxic than gentamicin and tobramycin, the difference is not considered profound [<a href="#rid1">1</a>]. Few data are available to determine the nephrotoxicity of <a class="drug drug_general" data-topicid="118322" href="/d/drug information/118322.html" rel="external">plazomicin</a> [<a href="#rid37">37,38</a>]. The relative nephrotoxic risk of a specific aminoglycoside will always depend on patient factors, comorbid disease, and the clinical setting in which the aminoglycoside is used.</p><p class="headingAnchor" id="H16"><span class="h2">Frequency of dosing</span><span class="headingEndMark"> — </span>The frequency of dosing may also be a risk factor for the development of aminoglycoside nephrotoxicity. This is supported by the favorable clinical data observed with the once-daily aminoglycoside dosing programs. In once-daily aminoglycoside therapy, a much larger loading dose is given every 24 to 48 hours. The rationale for this approach is to exploit the concentration-dependent bactericidal activity and postantibiotic effect of aminoglycosides. This approach to aminoglycoside dosing has demonstrated improved clinical efficacy and reduced nephrotoxicity relative to conventional aminoglycoside dosing [<a href="#rid21">21,22</a>]. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/475.html" rel="external">"Dosing and administration of parenteral aminoglycosides", section on 'Comparing extended-interval and traditional intermittent dosing'</a>.)</p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute kidney injury (AKI) due to aminoglycosides</strong> – AKI from aminoglycoside exposure typically manifests after five to seven days of therapy. The nonoliguric aspect of the kidney failure is secondary to a loss in renal concentrating ability believed to be the result of distal tubular damage. The acute tubular necrosis that occurs from aminoglycoside exposure is unlikely to be severe if detected early. (See <a class="local">'Nonoliguric acute kidney injury'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Electrolyte abnormalities</strong> – Hypomagnesemia, hypokalemia, hypocalcemia, and hypophosphatemia are infrequently observed. (See <a class="local">'Electrolyte abnormalities'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Course of AKI</strong> – Given that proximal tubules can regenerate, the usual course of aminoglycoside nephrotoxicity is one of recovery of kidney function. The plasma creatinine concentration usually returns to the prior baseline level within 21 days after cessation of therapy. However, resolution of the acute episode may be delayed and incomplete. (See <a class="local">'Course'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Several risk factors have been identified that increase the risk of aminoglycoside nephrotoxicity. The major risk factors are prolonged duration of therapy, advanced age, comorbid disease, reduced effective arterial volume, sepsis, hypoalbuminemia, concomitant medications, elevated plasma drug concentrations, type of aminoglycoside, and frequency of dosing. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="headingAnchor" id="H762197992"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Brian S Decker, MD, PharmD (deceased), who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Humes HD. Aminoglycoside nephrotoxicity. Kidney Int 1988; 33:900.</a></li><li><a class="nounderline abstract_t">Moore RD, Smith CR, Lipsky JJ, et al. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med 1984; 100:352.</a></li><li><a class="nounderline abstract_t">Meyer RD. Risk factors and comparisons of clinical nephrotoxicity of aminoglycosides. Am J Med 1986; 80:119.</a></li><li><a class="nounderline abstract_t">Bell S, Davey P, Nathwani D, et al. Risk of AKI with gentamicin as surgical prophylaxis. J Am Soc Nephrol 2014; 25:2625.</a></li><li><a class="nounderline abstract_t">McWilliam SJ, Antoine DJ, Smyth RL, Pirmohamed M. Aminoglycoside-induced nephrotoxicity in children. Pediatr Nephrol 2017; 32:2015.</a></li><li><a class="nounderline abstract_t">Laurent G, Kishore BK, Tulkens PM. Aminoglycoside-induced renal phospholipidosis and nephrotoxicity. Biochem Pharmacol 1990; 40:2383.</a></li><li class="breakAll">Chambers HF. Aminoglycosides. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th ed, Hardman JG, Limbird LE, Molinoff PB, et al. (Eds), McGraw-Hill, New York 2006.</li><li><a class="nounderline abstract_t">Chou CL, Chuang NC, Chiu HW, et al. Aminoglycosides use has a risk of acute kidney injury in patients without prior chronic kidney disease. Sci Rep 2022; 12:17212.</a></li><li><a class="nounderline abstract_t">Patel R, Savage A. Symptomatic hypomagnesemia associated with gentamicin therapy. Nephron 1979; 23:50.</a></li><li><a class="nounderline abstract_t">Houghton DC, English J, Bennett WM. Chronic tubulointerstitial nephritis and renal insufficiency associated with long-term "subtherapeutic" gentamicin. J Lab Clin Med 1988; 112:694.</a></li><li><a class="nounderline abstract_t">Schentag JJ, Jusko WJ. Renal clearance and tissue accumulation of gentamicin. Clin Pharmacol Ther 1977; 22:364.</a></li><li><a class="nounderline abstract_t">Dahlgren JG, Anderson ET, Hewitt WL. Gentamicin blood levels: a guide to nephrotoxicity. Antimicrob Agents Chemother 1975; 8:58.</a></li><li><a class="nounderline abstract_t">Prins JM, Büller HR, Kuijper EJ, et al. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993; 341:335.</a></li><li><a class="nounderline abstract_t">Smith CR, Moore RD, Lietman PS. Studies of risk factors for aminoglycoside nephrotoxicity. Am J Kidney Dis 1986; 8:308.</a></li><li><a class="nounderline abstract_t">Raveh D, Kopyt M, Hite Y, et al. Risk factors for nephrotoxicity in elderly patients receiving once-daily aminoglycosides. QJM 2002; 95:291.</a></li><li><a class="nounderline abstract_t">Galløe AM, Graudal N, Christensen HR, Kampmann JP. Aminoglycosides: single or multiple daily dosing? A meta-analysis on efficacy and safety. Eur J Clin Pharmacol 1995; 48:39.</a></li><li><a class="nounderline abstract_t">Paterson DL, Robson JM, Wagener MM. Risk factors for toxicity in elderly patients given aminoglycosides once daily. J Gen Intern Med 1998; 13:735.</a></li><li><a class="nounderline abstract_t">Bertino JS Jr, Booker LA, Franck PA, et al. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis 1993; 167:173.</a></li><li><a class="nounderline abstract_t">Cabrera J, Arroyo V, Ballesta AM, et al. Aminoglycoside nephrotoxicity in cirrhosis. Value of urinary beta 2-microglobulin to discriminate functional renal failure from acute tubular damage. Gastroenterology 1982; 82:97.</a></li><li><a class="nounderline abstract_t">Desai TK, Tsang TK. Aminoglycoside nephrotoxicity in obstructive jaundice. Am J Med 1988; 85:47.</a></li><li><a class="nounderline abstract_t">Munckhof WJ, Grayson ML, Turnidge JD. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother 1996; 37:645.</a></li><li><a class="nounderline abstract_t">Ferriols-Lisart R, Alós-Almiñana M. Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. Am J Health Syst Pharm 1996; 53:1141.</a></li><li><a class="nounderline abstract_t">Zager RA. Gentamicin effects on renal ischemia/reperfusion injury. Circ Res 1992; 70:20.</a></li><li><a class="nounderline abstract_t">Molitoris BA, Meyer C, Dahl R, Geerdes A. Mechanism of ischemia-enhanced aminoglycoside binding and uptake by proximal tubule cells. Am J Physiol 1993; 264:F907.</a></li><li><a class="nounderline abstract_t">Zager RA. Endotoxemia, renal hypoperfusion, and fever: interactive risk factors for aminoglycoside and sepsis-associated acute renal failure. Am J Kidney Dis 1992; 20:223.</a></li><li><a class="nounderline abstract_t">Wade JC, Smith CR, Petty BG, et al. Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside. Lancet 1978; 2:604.</a></li><li><a class="nounderline abstract_t">English J, Gilbert DN, Kohlhepp S, et al. Attenuation of experimental tobramycin nephrotoxicity by ticarcillin. Antimicrob Agents Chemother 1985; 27:897.</a></li><li><a class="nounderline abstract_t">Bennett WM, Wood CA, Houghton DC, Gilbert DN. Modification of experimental aminoglycoside nephrotoxicity. Am J Kidney Dis 1986; 8:292.</a></li><li><a class="nounderline abstract_t">Smith CR, Lipsky JJ, Laskin OL, et al. Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med 1980; 302:1106.</a></li><li><a class="nounderline abstract_t">Aronson JK, Reynolds DJ. ABC of monitoring drug therapy. Aminoglycoside antibiotics. BMJ 1992; 305:1421.</a></li><li><a class="nounderline abstract_t">McCormack JP, Jewesson PJ. A critical reevaluation of the "therapeutic range" of aminoglycosides. Clin Infect Dis 1992; 14:320.</a></li><li><a class="nounderline abstract_t">Whipple JK, Ausman RK, Franson T, Quebbeman EJ. Effect of individualized pharmacokinetic dosing on patient outcome. Crit Care Med 1991; 19:1480.</a></li><li><a class="nounderline abstract_t">Bartal C, Danon A, Schlaeffer F, et al. Pharmacokinetic dosing of aminoglycosides: a controlled trial. Am J Med 2003; 114:194.</a></li><li><a class="nounderline abstract_t">Destache CJ, Meyer SK, Bittner MJ, Hermann KG. Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides: a cost-benefit analysis. Ther Drug Monit 1990; 12:419.</a></li><li><a class="nounderline abstract_t">Burton ME, Ash CL, Hill DP Jr, et al. A controlled trial of the cost benefit of computerized bayesian aminoglycoside administration. Clin Pharmacol Ther 1991; 49:685.</a></li><li><a class="nounderline abstract_t">Lerner AM, Reyes MP, Cone LA, et al. Randomised, controlled trial of the comparative efficacy, auditory toxicity, and nephrotoxicity of tobramycin and netilmicin. Lancet 1983; 1:1123.</a></li><li><a class="nounderline abstract_t">Shaeer KM, Zmarlicka MT, Chahine EB, et al. Plazomicin: A Next-Generation Aminoglycoside. Pharmacotherapy 2019; 39:77.</a></li><li><a class="nounderline abstract_t">Wagenlehner FME, Cloutier DJ, Komirenko AS, et al. Once-Daily Plazomicin for Complicated Urinary Tract Infections. N Engl J Med 2019; 380:729.</a></li></ol></div><div id="topicVersionRevision">Topic 7214 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3290565" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Aminoglycoside nephrotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6364908" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Risk factors for nephrotoxicity in patients treated with aminoglycosides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3524214" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Risk factors and comparisons of clinical nephrotoxicity of aminoglycosides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24876113" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Risk of AKI with gentamicin as surgical prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27848094" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Aminoglycoside-induced nephrotoxicity in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2268362" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Aminoglycoside-induced renal phospholipidosis and nephrotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2268362" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Aminoglycoside-induced renal phospholipidosis and nephrotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36241669" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Aminoglycosides use has a risk of acute kidney injury in patients without prior chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/450167" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Symptomatic hypomagnesemia associated with gentamicin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3193025" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Chronic tubulointerstitial nephritis and renal insufficiency associated with long-term "subtherapeutic" gentamicin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/330081" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Renal clearance and tissue accumulation of gentamicin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1164007" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Gentamicin blood levels: a guide to nephrotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8094114" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Once versus thrice daily gentamicin in patients with serious infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3538855" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Studies of risk factors for aminoglycoside nephrotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11978900" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Risk factors for nephrotoxicity in elderly patients receiving once-daily aminoglycosides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7621846" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Aminoglycosides: single or multiple daily dosing? A meta-analysis on efficacy and safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9824518" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Risk factors for toxicity in elderly patients given aminoglycosides once daily.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8418164" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6171479" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Aminoglycoside nephrotoxicity in cirrhosis. Value of urinary beta 2-microglobulin to discriminate functional renal failure from acute tubular damage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3389381" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Aminoglycoside nephrotoxicity in obstructive jaundice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8722531" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8734674" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Effectiveness and safety of once-daily aminoglycosides: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1727686" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Gentamicin effects on renal ischemia/reperfusion injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8498544" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Mechanism of ischemia-enhanced aminoglycoside binding and uptake by proximal tubule cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1519603" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Endotoxemia, renal hypoperfusion, and fever: interactive risk factors for aminoglycoside and sepsis-associated acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/80528" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4026263" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Attenuation of experimental tobramycin nephrotoxicity by ticarcillin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3788967" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Modification of experimental aminoglycoside nephrotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6988713" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1486311" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : ABC of monitoring drug therapy. Aminoglycoside antibiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1571447" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A critical reevaluation of the "therapeutic range" of aminoglycosides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1959366" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effect of individualized pharmacokinetic dosing on patient outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12637133" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Pharmacokinetic dosing of aminoglycosides: a controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2127324" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides: a cost-benefit analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1905602" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A controlled trial of the cost benefit of computerized bayesian aminoglycoside administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6133153" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Randomised, controlled trial of the comparative efficacy, auditory toxicity, and nephrotoxicity of tobramycin and netilmicin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30511766" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Plazomicin: A Next-Generation Aminoglycoside.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30786187" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Once-Daily Plazomicin for Complicated Urinary Tract Infections.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
